← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Chantest, Inc.
Cleveland, OH
$2,163,277
Total funding
5
Grants
Funding over time
peak $631.9K · FY2006–13$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,163,277 · 5
By mechanism
R44$1,764,756 · 2
R43$398,521 · 3
Investigators at Chantest, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car$631,859
R44 · FY2012 · HL
Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car$552,449
R44 · FY2013 · HL
New drugs for treatment of atrial fibrillation$379,815
R44 · FY2003 · HL
New drugs for treatment of atrial fibrillation$200,633
R44 · FY2004 · HL
Development of a Complete Proarrhythmic Safety Profile for Drugs$149,322
R43 · FY2006 · HL
Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car$149,275
R43 · FY2010 · HL
New drugs for treatment of atrial fibrillation$99,924
R43 · FY2001 · HL